We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Humanitarian Device Exemption (Dystonia IRB)

This treatment has been approved for sale to the public.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00580658
First Posted: December 27, 2007
Last Update Posted: May 13, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Peter Konrad, Vanderbilt University
  Purpose
The purpose of this study is to allow patients to undergo deep brain stimulation (DBS) surgery for the treatment of dystonia. This is NOT a research study, but rather, a requirement by the FDA for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. Thus, this proposal request authorization by the IRB to allow patients at VUMC to access this HUD therapy.

Condition Intervention
Dystonia Device: Medtronic Activa Gpi

Study Type: Expanded Access     What is Expanded Access?
Official Title: Humanitarian Device Exemption for Medtronic Activa Dystonia Therapy

Resource links provided by NLM:


Further study details as provided by Peter Konrad, Vanderbilt University:

Study Start Date: May 2006
Estimated Study Completion Date: May 2020
Intervention Details:
    Device: Medtronic Activa Gpi
    Activa Therapy, Gpi
    Other Names:
    • DBS
    • Gpi
    • Activa Therapy
Detailed Description:
The purpose of this IRB approved study is to allow patients to undergo deep brain stimulation (DBS) surgery for the treatment of dystonia. This is NOT a research study, but rather, a requirement by the FDA for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. Use of DBS for dystonia is approved for humanitarian use by the FDA in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. Thus, this proposal request authorization by the IRB to allow patients at VUMC to access this HUD therapy.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   7 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients whose ages are in the range of 7 and 99 years old
  • Patients who are diagnosed with chronic, intractable (drug refractory)primary dystonia, including generalized and or segmental dystonia, hemidystonia, and cervical dystonia (torticollis)as determined by a neurologist or neurosurgeon.
  • Patients who have failed appropriate medical therapy as determined by the SMD conference

Exclusion Criteria:

  • Patients younger than 7 years old
  • Patients who are at significant surgical risk as determined by the neurosurgeon and/or anesthesiologist.
  • Patients who have not had an adequate trial of medical or non-surgical therapy as determined by the SMD conference.
  • Patients not deemed good candidates by the SMD conference group.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00580658


Locations
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Peter E Konrad, MD, Ph.D. Vanderbilt University, Dept. Neurosurgery
Principal Investigator: Hong Yu, MD Vanderbilt University, Dept. Neurosurgery
Principal Investigator: Thomas L Davis, MD Vanderbilt University, Dept. Neurology
Principal Investigator: John Y Fang, MD Vanderbilt University, Dept. Neurology
  More Information

Responsible Party: Peter Konrad, Professor, Director of Functional Neurosurgery, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00580658     History of Changes
Other Study ID Numbers: 060155
First Submitted: December 13, 2007
First Posted: December 27, 2007
Last Update Posted: May 13, 2016
Last Verified: May 2016

Keywords provided by Peter Konrad, Vanderbilt University:
Dystonia

Additional relevant MeSH terms:
Dystonia
Dystonic Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases


To Top